Table 2.
The change in human renal hemodynamics after long-term beta-blocker administration.
| β-Blockers | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug | References | RBF/RPF | Pglom | GFR | FF | RVR | Duration (weeks) | Participant number |
| Propranolol | Ibsen and Sederberg-Olsen, 1973 |  |
8–12 | 11 | ||||
| Falch et al., 1978 | |
2 | 11 (males) | |||||
| Falch et al., 1979b | |
32 | 13 | |||||
| O'Connor et al., 1979 | |
|
= | 4 | 12 (males) | |||
| Bauer and Brooks, 1979 | |
|
= | 4 | 8 (normal subjects) | |||
| Wilkinson et al., 1980 | |
8 | 15 | |||||
| Warren et al., 1981 | |
|
= |  |
4 | 13 | ||
| Bauer, 1983 | |
= | = | = | 20–25 | 14 (males) | ||
| Kimura et al., 1988 | = | 1 | 8 | |||||
| Malini et al., 1982 | |
= | |
12 | 12 | |||
| O'Connor and Preston, 1982 | |
|
= | = | 4 | 15 (males) | ||
| Malini et al., 1984 | |
= | = | 12 | 12 | |||
| van den Meiracker et al., 1989 | |
= | = | 3 | 10 (males) | |||
| Nadolol | O'Connor et al., 1982 | = | = | = | =† | 6 | 10 (males) | |
| Textor et al., 1982 | = | = | =† | 8 | 15 | |||
| O'Callaghan et al., 1983 | |
= | = | 10 | 10 (elderly) | |||
| Oxprenolol | Bellini et al., 1982 | = | |
7 | 7 | |||
| Atenolol | Wilkinson et al., 1980 | = | 8 | 15 | ||||
| Dreslinski et al., 1982 | = | = | |
4 | 10 | |||
| Bellini et al., 1982 | = | = | 7 | 7 | ||||
| O'Callaghan et al., 1983 | |
= | |
12 | 10 (elderly) | |||
| van den Meiracker et al., 1989 | = | = | |
3 | 10 (males) | |||
| Samuelsson et al., 1992 | = | = | = | =† | 4 | 17 | ||
| De Cesaris et al., 1993 | |
|
|
32 | 10 (hypertensive diabetics) | |||
| Leeman et al., 1993 | = | = | |
4 | 14 | |||
| Metoprolol | Sugino et al., 1984 | = | = | = | =† | 5–7 | 9 (males) | |
| Bisoprolol | Leeman et al., 1993 | = | = | |
4 | 14 | ||
| Parrinello et al., 2009 | = | = | |
=† | 52 | 36 | ||
| Labetalol | Rasmussen and Nielsen, 1981 | = | 4–15 | 11 | ||||
| Malini et al., 1982 | |
= | |
12 | 12 | |||
Participants are individuals with essential hypertension unless otherwise specified. RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR, renal vascular resistance; , significant decrease from control; , significant increase from control; =, no significant change from control.
†
Apparently anomalous results, given that for individual subjects RVR = MAP/RBF, MAP falls significantly, and yet neither RBF nor RVR are found to change significantly; the discrepancy arises from the statistical distribution within the study group.